Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
Arvinas (NASDAQ:ARVN), a clinical-stage biotech company focused on targeted protein degradation, has scheduled its Q2 2025 financial results announcement and corporate update for August 6, 2025, at 8:00 a.m. ET. The presentation will be accessible via live webcast in the Events and Presentations section of the company's investor relations website.
A recording of the webcast will be made available on www.arvinas.com after the event concludes.
Arvinas (NASDAQ:ARVN), un'azienda biotecnologica in fase clinica specializzata nella degradazione mirata delle proteine, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 e un aggiornamento aziendale per il 6 agosto 2025 alle 8:00 ET. La presentazione sarà disponibile in diretta streaming nella sezione Eventi e Presentazioni del sito web dedicato agli investitori dell'azienda.
Una registrazione della diretta sarà disponibile su www.arvinas.com al termine dell'evento.
Arvinas (NASDAQ:ARVN), una empresa biotecnológica en etapa clínica enfocada en la degradación dirigida de proteínas, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 y una actualización corporativa para el 6 de agosto de 2025 a las 8:00 a.m. ET. La presentación será accesible mediante una transmisión en vivo en la sección de Eventos y Presentaciones del sitio web de relaciones con inversionistas de la compañía.
Una grabación de la transmisión estará disponible en www.arvinas.com después de que concluya el evento.
Arvinas (NASDAQ:ARVN)는 표적 단백질 분해에 중점을 둔 임상 단계 바이오텍 회사로, 2025년 2분기 재무 실적 발표 및 기업 업데이트를 2025년 8월 6일 오전 8시(동부시간)에 예정하고 있습니다. 발표는 회사 투자자 관계 웹사이트의 이벤트 및 프레젠테이션 섹션에서 라이브 웹캐스트로 시청할 수 있습니다.
행사 종료 후 www.arvinas.com에서 웹캐스트 녹화본이 제공될 예정입니다.
Arvinas (NASDAQ:ARVN), une société biotechnologique en phase clinique spécialisée dans la dégradation ciblée des protéines, a prévu l'annonce de ses résultats financiers du deuxième trimestre 2025 et une mise à jour d'entreprise pour le 6 août 2025 à 8h00 ET. La présentation sera accessible en direct via un webcast dans la section Événements et Présentations du site web des relations investisseurs de la société.
Un enregistrement du webcast sera disponible sur www.arvinas.com après la fin de l'événement.
Arvinas (NASDAQ:ARVN), ein biotechnologisches Unternehmen in der klinischen Phase mit Fokus auf gezielten Proteinabbau, hat die Bekanntgabe der Finanzergebnisse für das 2. Quartal 2025 und ein Unternehmensupdate für den 6. August 2025 um 8:00 Uhr ET geplant. Die Präsentation wird über einen Live-Webcast im Bereich Veranstaltungen und Präsentationen auf der Investor-Relations-Website des Unternehmens zugänglich sein.
Eine Aufzeichnung des Webcasts wird nach der Veranstaltung auf www.arvinas.com verfügbar sein.
- None.
- None.
NEW HAVEN, Conn., July 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review financial results from the second quarter of 2025 and provide a corporate update during a live webcast on Wednesday, August 6, 2025, at 8:00 a.m. ET.
The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
When will Arvinas (ARVN) report Q2 2025 earnings?
How can I access Arvinas Q2 2025 earnings webcast?
Will there be a replay available of Arvinas Q2 2025 earnings call?
What does Arvinas (ARVN) specialize in?
